Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TLR4 | O00206 | 1/20 | 0.42 |
| ▸ | LIG1 | P18858 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL961415 | 0.98 | LMNA (0.41) | LMNATLR4LIG1ALDH1A1CYP19A1 | |
| SCHEMBL361341 | 0.94 | LMNA (0.43) | LMNALIG1ALDH1A1CYP19A1NPC1 | |
| SCHEMBL21595964 | 0.86 | LMNA (0.41) | LMNALIG1CYP19A1TDP1ATM | |
| SCHEMBL21595941 | 0.86 | LMNA (0.41) | LMNALIG1CYP19A1TDP1ATM | |
| SCHEMBL6434415 | 0.81 | ESR2 (0.48) | TLR4NPC1CA1CA2CA4 | |
| SCHEMBL1616775 | 0.81 | KDM4E (0.42) | TLR4LIG1ALDH1A1KMT2AMEN1 | |
| SCHEMBL8381617 | 0.81 | DDB1 (0.50) | TLR4CYP19A1KMT2ACA1CA2 | |
| SCHEMBL1138156 | 0.81 | NPC1 (0.45) | LMNATLR4ALDH1A1CYP19A1NPC1 | |
| SCHEMBL19993834 | 0.81 | LMNA (0.42) | LMNATLR4LIG1NPC1KMT2A | |
| SCHEMBL1617559 | 0.81 | TLR4 (0.42) | TLR4CYP19A1KMT2AMEN1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240300886-A1 | ARYLCYCLOHEXYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2024-09-12 | — | — | US | disclosed |
| US-20240254095-A1 | NMDA Receptor Antagonist and Use Thereof | SYNPHATEC (SHANGHAI) BIOPHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2024-08-01 | — | — | US | disclosed |
| CN-115190815-B | Arylcyclohexylamine derivatives and their use in the treatment of psychotic disorders | 吉尔伽美什制药公司 | 2024-06-18 | — | — | CN | disclosed |
| US-20240158340-A1 | PHOTOCATALYTIC ARYLATION OF CARBONYL COMPOUNDS AND METHODS FOR USING THE SAME | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2024-05-16 | — | — | US | disclosed |
| EP-4358946-A1 | ARYLCYCLOHEXYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS | Gilgamesh Pharmaceuticals, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| EP-4339189-A1 | NMDA RECEPTOR ANTAGONIST AND USE THEREOF | Synphatec (Shanghai) Biopharmaceutical Technology Co., Ltd. (CN) | 2024-03-20 | — | — | EP | disclosed |
| CN-113234036-B | NMDA receptor antagonists and uses thereof | 斯莱普泰(上海)生物医药科技有限公司 | 2023-07-14 | — | — | CN | disclosed |
| WO-2022272174-A1 | ARYLCYCLOHEXYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| US-20220409555-A1 | ARYLCYCLOHEXYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS | GILGAMESH PHARMACEUTICALS INC (US) | 2022-12-29 | — | — | US | disclosed |
| US-20220409555-A1 | ARYLCYCLOHEXYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS | GILGAMESH PHARMACEUTICALS INC (US) | 2022-12-29 | — | — | US | disclosed |
| EP-1720873-A1 | DIAZA-SPIROPIPERIDINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-11-15 | — | — | EP | disclosed |
| EP-1678177-A1 | TRIAZA-SPIROPIPERIDINE DERIVATIVES FOR USE AS GLYT-1 INHIBITORS IN THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005068463-A1 | DIAZA-SPIROPIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-07-28 | — | — | WO | disclosed |
| US-20050154001-A1 | Diaza-spiropiperidine derivatives | HOFFMANN-LA ROCHE INC. | 2005-07-14 | — | — | US | disclosed |
| US-20050107373-A1 | E.g., 1-phenyl-8-(2-phenyl-cyclohexyl)-1,3,8-triaza-spiro[4.5]decan-4-one; activation of N-methylaspartic acid receptors via Glycine (Gly t-1) inhibition; psychoses; analgesics; neurodegenerative and psychological disorders; schizophrenia; cognition activators; antidepressants; Alzheimer's disease | F. HOFFMANN-LA ROCHE AG (CH) | 2005-05-19 | — | — | US | disclosed |
| WO-2005040166-A1 | TRIAZA-SPIROPIPERIDINE DERIVATIVES FOR USE AS GLYT-1 INHIBITORS IN THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | F.HOFFMANN-LA ROCHE AG (CH) | 2005-05-06 | — | — | WO | disclosed |
| WO-2005040166-A1 | TRIAZA-SPIROPIPERIDINE DERIVATIVES FOR USE AS GLYT-1 INHIBITORS IN THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | F.HOFFMANN-LA ROCHE AG (CH) | 2005-05-06 | — | — | WO | disclosed |
| EP-0073849-A1 | Novel phenyl-1,2,3,4-tetrahydrocarbazoles, their preparation and pharmaceutical compositions containing them | SCHERING CORPORATION (US) | 1983-03-16 | — | — | EP | disclosed |
| US-4292323-A | Phenyl-1,2,3,4-tetrahydrocarbazoles and use thereof | SCHERING CORPORATION (US) | 1981-09-29 | — | — | US | disclosed |
| US-4150135-A | ANALGESICS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1979-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240300886-A1 | ARYLCYCLOHEXYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS | HTR2C, PNMT, HTR2A | LMNA 3505/4885TLR4 2435/4885LIG1 4472/4885 |
| US-20240158340-A1 | PHOTOCATALYTIC ARYLATION OF CARBONYL COMPOUNDS AND METHODS FOR USING THE SAME | AHR, CBR3, AADAC | LMNA 1467/4885TLR4 3743/4885LIG1 864/4885 |
| US-20050107373-A1 | E.g., 1-phenyl-8-(2-phenyl-cyclohexyl)-1,3,8-triaza-spiro[4.5]decan-4-one; activation of N-methylaspartic acid receptors via Glycine (Gly t-1) inhibition; psychoses; analgesics; neurodegenerative and psychological disorders; schizophrenia; cognition activators; antidepressants; Alzheimer's disease | GRIN1, GRIN2A, GRM1 | LMNA 4217/4885TLR4 150/4885LIG1 2334/4885 |
| US-20240254095-A1 | NMDA Receptor Antagonist and Use Thereof | GRIN2B, GRIN1, GRIN3A | LMNA 4328/4885TLR4 358/4885LIG1 2779/4885 |
| US-20220409555-A1 | ARYLCYCLOHEXYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS | HTR2C, PNMT, HTR2A | LMNA 3550/4885TLR4 2696/4885LIG1 4295/4885 |
| US-20050154001-A1 | Diaza-spiropiperidine derivatives | HCN3, SCN3A, SLC6A3 | LMNA 3896/4885TLR4 2953/4885LIG1 3727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.